Other FASN inhibitors, including C75, EGFR, Fasnall, and TVB-3166, also demonstrate significant inhibitory effects on breast cancer, although they face limitations in clinical application [160,161,162,163]. This evidence concerns the gene EGFR and breast carcinoma.